C2 cersoc (D18 :1 / 2 : 0)

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

C2 Ceramide (d18:1/2:0) has been used to treat protoplasts for reactive oxygen species generation and as an substrate for sphingomyelin synthase 2 enzyme. It is suitable for use as an exogenous supplement in hippocampal cell cultures for the production of 2-hydroxyeicosatetraenoic acid (12-(S)-HETE).

Biochem/physiol Actions

C2 ceramide inhibits the progression of human bronchocarcinoma by modulating the matrix metallopeptidases-2 levels. It also inhibits glioma invasion and induces apoptosis in HT-29 and HCT-116 human colon cancer cells. Treatment of myotubes with C2-ceramide leads to decrease in glucose uptake and glycogen synthesis. C2 along with C6 ceramides induces insulin resistance in myoblastic C2C12 cell line and L6 myotubes.

General description

C2 Ceramide (d18:1/2:0) is a short-chain ceramide. In general ceramides are synthesized by de novo pathway from palmitic acid via series of intermediates to ceramidein the presence of dihydroceramide Δ4-desaturase.

Packaging

5 mL Amber Glass Screw Cap Vial (860502P-5mg)